Jinxin Fertility (锦欣生殖) Placement - Setting up for Acquisitions

Jinxin Fertility: Takeaways from Wuhan NDR and Yunnan Acquisition

China: 3rd Child Policy and 3 Beneficiaries

Jinxin Fertility: Long Term IVF Story Intact Despite Potential Post Results De-Rating

APAC IPOs & Placements

Zhen Zhou, Toh

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Capital Markets

Jinxin Fertility Group  / Equity Capital Markets

<div>
<p>A shareholder of <a href="https://www.smartkarma.com/entities/jinxin-fertility-group-ltd" target="_blank" data-smartkarma-citation="entities:28003:1" rel="noopener">Jinxin Fertility Co Ltd (1951 HK)</a>  is looking to raise US$100m by selling about 42m of shares or about 1.7% of total shares outstanding.</p>
<p>Our previous coverage on Jinxin Fertility:</p>
</div><div><ul style="list-style-type: disc;">
<li><a href="https://www.smartkarma.com/insights/jinxin-fertility-pre-ipo-strong-foothold-in-sichuan-but-weak-sentiment-for-sector" target="_blank" rel="noopener">Jinxin Fertility (锦欣生殖) Pre-IPO: Strong Foothold in Sichuan but Weak Sentiment for Sector</a></li>
<li><a href="https://www.smartkarma.com/insights/jinxin-fertility-ipo-worth-a-look-given-the-sector-existing-shareholders-and-cornerstone" target="_blank" rel="noopener">Jinxin Fertility (锦欣生殖) IPO - Worth a Look Given the Sector, Existing Shareholders and Cornerstone</a></li>
<li><a href="https://www.smartkarma.com/insights/jinxin-fertility-post-ipo-trading-fairly-valued" target="_blank" rel="noopener">Jinxin Fertility (锦欣生殖) Post-IPO Trading: Fairly Valued</a></li>
<li>January 2020 Placement: <a href="https://www.smartkarma.com/insights/jinxin-fertility-placement-a-good-point-of-entry" target="_blank" rel="noopener">Jinxin Fertility (锦欣生殖) Placement - A Good Point of Entry</a>
</li>
<li>July 2020 Placement: <a href="https://www.smartkarma.com/insights/jinxin-fertility-placement-sound-fundamentals" target="_blank" data-smartkarma-citation="insights:41057" rel="noopener">Jinxin Fertility Placement: Sound Fundamentals</a> </li>
<li>Jan 2021 Placement: <a href="https://www.smartkarma.com/insights/jinxin-fertility-placement-only-warburg-selling-this-time" target="_blank" data-smartkarma-citation="insights:46756" rel="noopener">Jinxin Fertility (锦欣生殖) Placement - Only Warburg Selling This Time</a> </li>
<li>NDR takeaways: <a href="https://www.smartkarma.com/insights/jinxin-fertility-takeaways-from-wuhan-ndr-and-yunnan-acquisition" target="_blank" data-smartkarma-citation="insights:53368" rel="noopener">Jinxin Fertility: Takeaways from Wuhan NDR and Yunnan Acquisition</a>
</li>
<li>Industry outlook: <a href="https://www.smartkarma.com/insights/china-3rd-child-policy-and-3-beneficiaries" target="_blank" data-smartkarma-citation="insights:52386" rel="noopener">China: 3rd Child Policy and 3 Beneficiaries</a> </li>
</ul></div>


A shareholder of Jinxin Fertility Co Ltd (1951 HK)  is looking to raise US$100m by selling about 42m of shares or about 1.7% of total shares outstanding.
Our previous coverage on Jinxin Fertility:

Jinxin Fertility (锦欣生殖) Pre-IPO: Strong Foothold in Sichuan but Weak Sentiment for Sector
Jinxin Fertility (锦欣生殖) IPO - Worth a Look Given the Sector, Existing Shareholders and Cornerstone
Jinxin Fertility (锦欣生殖) Post-IPO Trading: Fairly Valued
January 2020 Placement: Jinxin Fertility (锦欣生殖) Placement - A Good Point of Entry

July 2020 Placement: Jinxin Fertility Placement: Sound Fundamentals 
Jan 2021 Placement: Jinxin Fertility (锦欣生殖) Placement - Only Warburg Selling This Time 
NDR takeaways: Jinxin Fertility: Takeaways from Wuhan NDR and Yunnan Acquisition

Industry outlook: China: 3rd Child Policy and 3 Beneficiaries 


Jinxin Fertility (锦欣生殖) Placement -   A Familiar Name by Now and Don't Expect Extravagant Returns